| Identification | Back Directory | [Name]
NVP-BEZ235 (hydrochloride) | [CAS]
2319647-83-9 | [Synonyms]
NVP-BEZ235 (hydrochloride)
4-[2,3-dihydro-3-methyl-2-oxo-8-(3-quinolinyl)-1H-imidazo[4,5-c]quinolin-1-yl]-α,α-dimethyl-benzeneacetonitrile,monohydrochloride | [Molecular Formula]
C30H24ClN5O | [MOL File]
2319647-83-9.mol | [Molecular Weight]
505.997 |
| Hazard Information | Back Directory | [Uses]
Dactolisib (BEZ235) hydrochloride is an orally active, dual pan-class I PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR with IC50 of 4 nM/5 nM/7 nM/75 nM and 20.7 nM, respectively. Dactolisib hydrochloride (BEZ235) inhibits mTORC1 and mTORC2[1]. | [References]
[1] Maira SM, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther, 2008, 7(7), 1851-1863. DOI:10.1158/1535-7163.MCT-08-0017
[2] Roper J, et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS One, 2011, 6(9), e25132. DOI:10.1371/journal.pone.0025132
[3] Lee M, et al. Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. Clin Cancer Res. 2015 Jul 15;21(14):3204-15. DOI:10.1158/1078-0432.CCR-15-0288 |
|
|